Endocrinology and metabolism clinics of North America
The most recent articles from:
March 2011
-
Endocrinol. Metab. Clin. North Am. · Mar 2011
ReviewThe clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Chromogranin A, although it exhibits limitations, is currently the most useful general tumor biomarker available for use in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (NETs). The value of the chromogranin A lies in its universal cosecretion by the majority of neuroendocrine cells that persists after malignant transformation. Clinicians aware of the physiologic role of chromogranin A and its secretion in a variety of non-NET-related pathologic conditions can use this protein as a moderately effective tumor biomarker in the management of GEP-NETs.